I am currently serving as a Researcher at the University of Turin, Department of Oncology, based at the Candiolo Cancer Institute – FPO, IRCCS, in the scientific field of Clinical Biochemistry and Molecular Biology.
My research primarily focuses on malignancies characterized by poor prognosis and therapeutic resistance, with the overarching goal of elucidating molecular mechanisms underlying treatment response and disease progression. In particular, my studies include investigations on metastatic colorectal cancer and pleural mesothelioma. Within this framework, I have been involved in the analysis of genetic and epigenetic alterations — including gene methylation — as predictive biomarkers of therapeutic response, as well as in the evaluation of the efficacy of anti-cancer therapies in patient cohorts with unfavorable clinical outcomes.
In the broader context of precision oncology, my research also encompasses the analysis of cell-free DNA as a diagnostic and prognostic tool in solid tumors.
I am currently serving as a Researcher at the University of Turin, Department of Oncology, based at the Candiolo Cancer Institute – FPO, IRCCS, in the scientific field of Clinical Biochemistry and Molecular Biology.
My research primarily focuses on malignancies characterized by poor prognosis and therapeutic resistance, with the overarching goal of elucidating molecular mechanisms underlying treatment response and disease progression. In particular, my studies include investigations on metastatic colorectal cancer and pleural mesothelioma. Within this framework, I have been involved in the analysis of genetic and epigenetic alterations — including gene methylation — as predictive biomarkers of therapeutic response, as well as in the evaluation of the efficacy of anti-cancer therapies in patient cohorts with unfavorable clinical outcomes.
In the broader context of precision oncology, my research also encompasses the analysis of cell-free DNA as a diagnostic and prognostic tool in solid tumors.